Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Bianchi

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Brain Injury|February 15, 2021
Clinical course of SARS-CoV-2 infection in patients with severe acquired brain injury and a disorder of consciousness: an observational studyAntonio Caronni, Emanuele Liaci, Anna Bianchi, et al.
Cancer Immunology, Immunotherapy : CII|June 23, 2025
Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancerNilesh U Deshpande, Anna Bianchi, Haleh Amirian, et al.
Elife|September 15, 2022
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical studyIago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, et al.
Plos One|April 12, 2013
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patientsMarina Chiara Garassino, Sheila Piva, Nicla La Verde, et al.
Molecular Cancer Therapeutics|September 14, 2021
Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic CancerAustin R Dosch, Samara Singh, Xizi Dai, et al.
Blood Advances|April 6, 2021
The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myelomaBrittany C Lipchick, Adam Utley, Zhannan Han, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Cell-specific nanoengineering strategy disrupts tolerogenic signaling from myeloid-derived suppressor cells to invigorate antitumor immunity in pancreatic cancerNilesh U Deshpande, Anna Bianchi, Haleh Amirian, et al.
International Journal of Molecular Sciences|December 30, 2025
Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal CancerAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Cell Reports|October 4, 2018
XBP1-KLF9 Axis Acts as a Molecular Rheostat to Control the Transition from Adaptive to Cytotoxic Unfolded Protein ResponseEmily E Fink, Sudha Moparthy, Archis Bagati, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Brain Injury|February 15, 2021
Clinical course of SARS-CoV-2 infection in patients with severe acquired brain injury and a disorder of consciousness: an observational studyAntonio Caronni, Emanuele Liaci, Anna Bianchi, et al.
Cancer Immunology, Immunotherapy : CII|June 23, 2025
Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancerNilesh U Deshpande, Anna Bianchi, Haleh Amirian, et al.
Elife|September 15, 2022
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical studyIago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, et al.
Plos One|April 12, 2013
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patientsMarina Chiara Garassino, Sheila Piva, Nicla La Verde, et al.
Molecular Cancer Therapeutics|September 14, 2021
Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic CancerAustin R Dosch, Samara Singh, Xizi Dai, et al.
Blood Advances|April 6, 2021
The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myelomaBrittany C Lipchick, Adam Utley, Zhannan Han, et al.
JCI Insight|June 22, 2026
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancerErin M Dickey, Harper M Marsh, Camilla Rydberg-Millrud, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Cell-specific nanoengineering strategy disrupts tolerogenic signaling from myeloid-derived suppressor cells to invigorate antitumor immunity in pancreatic cancerNilesh U Deshpande, Anna Bianchi, Haleh Amirian, et al.
International Journal of Molecular Sciences|December 30, 2025
Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal CancerAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Cell Reports|October 4, 2018
XBP1-KLF9 Axis Acts as a Molecular Rheostat to Control the Transition from Adaptive to Cytotoxic Unfolded Protein ResponseEmily E Fink, Sudha Moparthy, Archis Bagati, et al.
Pageof 12